Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06986993 · ClinicalTrials.gov registry record · Phase 4
Impact of Semaglutide on Tobacco Use and Related Health Behaviors
A Phase 4 study of Tobacco Use, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06986993: Recruiting Phase 4 study of Tobacco Use, sponsored by University of Oklahoma.
NCT06986993 is a Phase 4 study of Tobacco Use that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 40 participants, below the 379-participant average among 76 other Tobacco Use trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06986993, a Phase 4 study of Tobacco Use, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via continuous glucose monitoring \[CGM\], etc.) in adult smokers with obesity (n = 40). We will integrate molecular biology procedures (e.g., epigenetics) to maximize internal validity with real-world smartphone-based ecological momentary assessment (EMA) surveys to maximize external validity
Primary Outcome
Changes in number of cigarettes smoked per day
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (1)
Oklahoma
- Health Promotion Research Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 4 |
What NCT06986993 shows while recruiting
NCT06986993 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 379-participant average among 76 other Tobacco Use trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Tobacco Use appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06986993 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06986993 about?
NCT06986993 is a clinical study titled "Impact of Semaglutide on Tobacco Use and Related Health Behaviors". This pilot randomized trial will assess the impact of 12 weeks of semaglutide administration (vs placebo) on changes in: (i) tobacco use and related factors (nicotine craving, withdrawal, motivation to quit, etc.) and (ii) biological biomarkers of health (e.g., epigenetics, glucose variability via c...
What is the current status of trial NCT06986993?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2024-07-01. Estimated completion is 2028-06-30.
What conditions does trial NCT06986993 study?
This clinical trial studies the following conditions: Tobacco Use.
What interventions are being tested in trial NCT06986993?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06986993?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06986993 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06986993's enrollment target sits among peer trials
40 59th of 76 higher than 16 of 76 other Tobacco Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Intervention for Tobacco Use (EXIT) for People Experiencing Homelessness
RECRUITING · Phase 4
-
Minocycline and Tobacco Craving in Smokers With Schizophrenia
COMPLETED · Phase 4
-
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
RECRUITING · NA
-
Effect of Cannabis on Cigarette Use Behavior
RECRUITING · Phase 1
-
Neural Mechanisms Connecting Deficient Sleep and Smoking Relapse
RECRUITING · Phase 2
-
Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI